Results 231 to 240 of about 1,125,330 (386)

Engineering Immune Cell to Counteract Aging and Aging‐Associated Diseases

open access: yesAdvanced Science, EarlyView.
This review highlights a paradigm shift in which advanced immune cell therapies, initially developed for cancer, are now being harnessed to combat aging. By engineering immune cells to selectively clear senescent cells and remodel pro‐inflammatory tissue microenvironments, these strategies offer a novel and powerful approach to delay age‐related ...
Jianhua Guo   +5 more
wiley   +1 more source

Drugs anticipated to be selected for Medicare price negotiation in 2026 for implementation in 2028. [PDF]

open access: yesJ Manag Care Spec Pharm
Cousin EM   +4 more
europepmc   +1 more source

In Situ Liquid‐Cell Transmission Electron Microscopy Insights Into Lithium‐Ion Battery Materials Degradation: Challenges and Emerging Solutions

open access: yesAdvanced Science, EarlyView.
Lithium‐ion battery degradation arises from complex, localized processes during operation, limiting long‐term performance. In situ electrochemical liquid cell TEM provides unique access to these mechanisms. This review summarizes degradation phenomena revealed by liquid cell TEM, traces the evolution of the three main cell designs, compares their ...
Walid Dachraoui, Rolf Erni
wiley   +1 more source

Modulation of Network Plasticity Opens Novel Therapeutic Possibilities in Cancer, Diabetes, and Neurodegeneration

open access: yesAdvanced Science, EarlyView.
Plasticity changes of molecular networks form a cellular learning process. Signaling network plasticity promotes cancer, metastasis, and drug resistance development. 55 plasticity‐related cancer drug targets are listed (20 having already approved drugs, 9 investigational drugs, and 26 being drug target candidates).
Márk Kerestély   +5 more
wiley   +1 more source

PIK3CA Mutations Downregulate PPT1 to Promote Adipogenesis by Suppressing P300 Depalmitoylation and Phase Separation

open access: yesAdvanced Science, EarlyView.
This study demonstrates that somatic PIK3CA mutations suppress PPT1 expression via activation of the PI3K–AKT–c‐JUN axis. This reduction in PPT1 weakens its interaction with P300, thereby increasing palmitoylation at C1176 of P300 and protecting P300 from lysosomal degradation.
Hongrui Chen   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy